Relay Therapeutics (RLAY) has a profit margin of -2837.31%, below the Healthcare sector average of 17.63%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
Relay Therapeutics (RLAY) currently reports a profit margin of -2837.31% as of September 2026. That compares with -3561.43% in the prior-year period — up 20.3% year over year. That is below the Healthcare sector average of 17.63%. Use the charts on this page to explore Relay Therapeutics's profit margin history and peer comparisons.
Relay Therapeutics's profit margin increased from -3561.43% to -2837.31% — a 20.3% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Relay Therapeutics's profit margin of -2837.31% is lower than the Healthcare sector average of 17.63%. That is roughly 16195.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' profit margin, but Relay Therapeutics's current -2837.31% should be judged against Healthcare norms (sector average: 17.63%) and against RLAY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current profit margin of -2837.31%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 17.63%. From there, open related valuation or income-statement pages for Relay Therapeutics, and consider following RLAY for alerts when major investors trade the stock.